Department of Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka, Japan.
Rheumatol Int. 2010 Jan;30(3):405-8. doi: 10.1007/s00296-009-0948-x. Epub 2009 May 16.
We report a case of sudden onset of late infection after TKA inflamed by anti-TNFalpha therapy, Infliximab, in a 54-year-old woman with RA. Infliximab therapy was started 3 years and 8 months after TKAs as a result of multiple arthritides showing high inflammation of RA. One week after the third administration of Infliximab, the patient suffered sudden knee pain and infectious clinical symptoms, and bacteria (MSSA) were detected by joint effusion culture. She was successfully treated by open debridement with antibiotics-loaded calcium phosphate bone paste and cement and the prostheses were retained. Early diagnosis and operative treatment might be the key to controlling infected TKA without removing the implant. This present case might indicate a serious risk of immunosuppressive effects caused by Infliximab.
我们报告了一例类风湿关节炎(RA)患者在接受抗 TNF-α 治疗(英夫利昔单抗)后,因多关节炎炎症反应高,在膝关节置换术后 3 年 8 个月时开始使用英夫利昔单抗治疗后发生晚期感染的病例。第三次英夫利昔单抗治疗后 1 周,患者出现突发膝关节疼痛和感染性临床症状,关节液培养出 MSSA 细菌。通过开放性清创术并用抗生素载磷酸钙骨水泥进行治疗,并保留了假体,患者成功治愈。早期诊断和手术治疗可能是控制感染性膝关节置换术而不取出假体的关键。本病例可能表明英夫利昔单抗的免疫抑制作用存在严重风险。